Category: Federal Forum Posters
Purpose: Human Immunodeficiency Virus infection (HIV) is associated with an increased risk of cardiovascular disease (CVD) due to the persistent state of immune dysfunction and chronic inflammation caused by the virus in addition to the lipid abnormalities related to antiretroviral treatment. Optimization of therapy is crucial to decrease morbidity and mortality in this patient population, especially when presented with traditional CVD risk factors such as diabetes, dyslipidemia and elevated blood pressure. The purpose of this study is to identify which additional CVD risk factors are present and if the current medication therapy management for these risk factors is optimal.
Methods: This study is a retrospective, cohort, chart review of patients identified from a password-protected site. De-identified data will be collected from men and women aged 40 years or older diagnosed with HIV and presenting with any additional CVD risk factors, such as diagnosis of diabetes, hypertension, hyperlipidemia and Hepatitis C co-infection. Clinical variables will include most recent low-density lipoproteins, triglycerides, high-density lipoproteins, creatinine phosphokinase, systolic and diastolic blood pressure, serum creatinine, creatinine clearance, hemoglobin A1c, blood glucose, aspartate aminotransferase and alanine aminotransferase, weight, body mass index, viral load, and smoking status. 10-year ASCVD (atherosclerotic cardiovascular disease) risk score will be calculated. Date of HIV diagnosis and duration on antiretroviral therapy as well as demographic data such as age, gender, ethnicity, will be recorded. Patients will be excluded if they are pregnant, nursing, have a creatinine phosphokinase level greater than five times the upper normal limit, and had no follow-up within 6 months. The primary outcome measure will be identifying which additional CVD risks our HIV patient population have, while the secondary outcome is assessing if patients are receiving optimal medication therapy for prevention of cardiovascular events based on current guidelines. Descriptive statistics will be used to summarize the data.
Results: Not Applicable
Conclusion: Not Applicable
Sonjela Bulku– PGY1 Pharmacy Practice Resident, VA New York Harbor Healthcare System, Brooklyn, NY